Cyclopharm (ASX:CYC) said the United States Patent and Trademark Office has approved a patent extension for the company's lung imaging technology, extending protection to 2031 from the original expiration date of 2026, according to a Wednesday filing with the Australian bourse.

The patent extension ensures uninterrupted US market exclusivity for the technology, the filing said.